Cencora, Inc. COR
Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance) niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B | $189.89B | $179.59B | $167.94B | $153.14B | $146.85B |
| Cost of revenue | $309.85B | $284.05B | $253.21B | $230.29B | $207.05B | $184.70B | $174.45B | $163.33B | $148.60B | $142.58B |
| Gross profit | $11.48B | $9.91B | $8.96B | $8.30B | $6.94B | $5.19B | $5.14B | $4.61B | $4.55B | $4.27B |
| SG&A | $6.49B | $5.66B | $5.31B | $4.85B | $3.59B | $2.77B | $2.66B | $2.46B | $2.13B | $2.09B |
| Total operating expenses | $6.99B | $6.09B | $5.72B | — | — | — | — | — | — | — |
| Operating income | $2.63B | $2.18B | $2.34B | $2.37B | $2.35B | -$5.14B | $1.11B | $1.44B | $1.06B | $1.53B |
| Pre-tax income | $2.26B | $2.00B | $2.16B | $2.18B | $2.22B | -$5.29B | $967.1M | $1.18B | $917.9M | $1.39B |
| Income tax | $690.5M | $484.7M | $428.3M | $516.5M | $677.3M | $1.89B | $113.0M | $438.5M | $553.4M | $37.0M |
| Net income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B | -$3.41B | $855.4M | $1.66B | $364.5M | $1.43B |
| EPS, basic | 8.02 | 7.60 | 8.62 | 8.15 | 7.48 | -16.65 | 4.07 | 7.61 | 1.67 | 6.73 |
| EPS, diluted | 7.96 | 7.53 | 8.53 | 8.04 | 7.39 | -16.65 | 4.04 | 7.53 | 1.64 | 6.32 |
| Shares, diluted (wtd. avg.) | $195.2M | $200.3M | $204.6M | $211.2M | $208.5M | $204.8M | $211.8M | $220.3M | $221.6M | $226.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.36B | $3.13B | $2.59B | $3.39B | $2.55B | $4.60B | $3.37B | $2.49B | $2.44B | $2.74B |
| Receivables | $25.23B | $23.87B | $20.91B | $18.45B | $18.17B | $13.85B | $12.39B | $11.31B | $10.30B | $9.18B |
| Inventory | $20.49B | $19.00B | $17.45B | $15.56B | $15.37B | $12.59B | $11.06B | $11.92B | $11.46B | $10.72B |
| Total current assets | $52.24B | $47.72B | $42.80B | $39.59B | $38.80B | $33.06B | $28.13B | $25.89B | $24.30B | $22.85B |
| Property, plant and equipment | $2.54B | $2.18B | $2.14B | $2.14B | $2.16B | $1.48B | $1.77B | $1.89B | $1.80B | $1.53B |
| Goodwill | $13.68B | $9.32B | $9.57B | $8.50B | $9.03B | $6.71B | $6.71B | $6.66B | $6.04B | $5.99B |
| Other intangibles | $3.77B | $4.00B | $4.43B | $4.33B | $5.26B | $1.89B | $2.29B | $2.95B | $2.83B | $2.97B |
| Total assets | $76.59B | $67.10B | $62.56B | $56.56B | $57.34B | $44.27B | $39.17B | $37.67B | $35.32B | $33.64B |
| Accounts payable | $54.72B | $50.94B | $45.84B | $40.19B | $38.01B | $31.71B | $28.39B | $26.84B | $25.40B | $23.93B |
| Short-term debt | $117.8M | $576.3M | $641.3M | $1.07B | $300.2M | $501.3M | $139.0M | $151.7M | $12.1M | $610.2M |
| Total current liabilities | $57.82B | $54.28B | $48.83B | $43.48B | $41.36B | $33.85B | $29.58B | $27.87B | $26.82B | $25.28B |
| Long-term debt | $7.54B | $3.81B | $4.15B | $4.63B | $6.38B | $3.62B | $4.03B | $400.0M | $3.43B | $3.58B |
| Retained earnings | $6.53B | $5.42B | $4.32B | $2.98B | $1.67B | $518.3M | $4.24B | $3.72B | $2.40B | $2.30B |
| Total equity | $1.51B | $645.9M | $666.3M | $71.3M | $584.4M | -$839.6M | $2.99B | $3.05B | $2.06B | $2.13B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.88B | $3.48B | $3.91B | $2.70B | $2.67B | $2.21B | $2.34B | $1.41B | $1.50B | $3.18B |
| Depreciation and amortisation | $1.05B | $1.09B | $963.9M | $693.9M | $505.2M | $391.1M | $462.4M | $465.1M | $397.6M | $364.7M |
| Stock-based compensation | $148.0M | $148.0M | $124.6M | $93.4M | $99.6M | $74.4M | $58.9M | $62.3M | $62.2M | $65.0M |
| Capital expenditure | $668.0M | $487.2M | $458.4M | $496.3M | $438.2M | $369.7M | $310.2M | $336.4M | $466.4M | $464.6M |
| Investing cash flow | -$4.98B | -$618.1M | -$2.60B | -$368.4M | -$6.14B | -$379.9M | -$375.8M | -$1.11B | -$498.0M | -$3.17B |
| Financing cash flow | $2.25B | -$2.33B | -$2.22B | -$1.75B | $1.95B | -$603.6M | -$1.09B | -$242.9M | -$1.31B | $565.1M |
| Dividends paid | $437.1M | $416.2M | $398.8M | $391.7M | $366.6M | $343.6M | $339.0M | $333.0M | $320.3M | $288.5M |
| Buybacks | $435.5M | $1.49B | $1.18B | $483.7M | $82.2M | $420.4M | $674.0M | $639.2M | $329.9M | $2.27B |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140859-26-000012.
Others in SIC 5122
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MCK | MCKESSON CORP | $105.86B | 23.7x | 12.4% |
| CAH | CARDINAL HEALTH INC | $57.49B | 34.2x | 14.2% |
| HLF | HERBALIFE LTD. | $1.30B | 5.6x | 0.9% |
| NUS | NU SKIN ENTERPRISES, INC. | $235.6M | 1.5x | -14.3% |
| COSM | Cosmos Health Inc. | $27.5M | — | 19.9% |
| HWH | HWH International Inc. | $14.5M | — | -30.8% |
| MEDS | DataMeds AI, Inc. | $2.8M | — | 28.7% |
| HKPD | Cellyan Biotechnology Co., Ltd | — | — | — |